COMPANY ANNOUNCEMENT
Centris Pharmaceutical Inc Issues Voluntary Recall of Estradiol
Summary
| FDA Announcement Date: | May 7th, 2026 |
| Product Type: | Drugs |
| Reason for Announcement: | Product is tainted with EPE-A(Enhanced Profile Estrogen A) |
| Company Name: | Centris Pharmaceuticals, Inc |
| Brand Name: | Centris Pharmaceuticals, Inc |
| Product Description: | Oral Contraceptives, Hormonal Birth Control, Hormone Replacement Therapy |
Company Announcement
FOR IMMEDIATE RELEASE — May 7th, 2026 — Providence, Rhode Island, Centris Pharmaceutical Incorporated is voluntarily recalling Estradiol Valerate in both oil and tablet form and Estradiol Hemihydrate in tablet form. Centris Pharmaceuticals has found that these products are tainted in an accidental process violation with Enhanced Profile Estrogen-A. While this serves much the same purpose as estradiol, it has substantially stronger feminizing effects and lasts much longer in the body, potentially making the feminization more severe. This is complicated by the fact that this material inhibits the dysphoria that results from these bodily changes. This is likely to result in substantial under-reporting of the effects. The mixture also renders this an unapproved formulation with uncertain side-effect profiles.
Risk Statement: Consumption of products contaminated with Enhanced Profile Estrogen-A may cause feminizing effects such as soft skin, fat redistribution, breast growth(gynocomastia), mood changes, and weight gain, as well as a higher estradiol level over time. Other side effects are rare. In addition, it may cause mental changes that result in lessened dysphoria from these bodily changes. Some of these bodily changes are permanent and cannot be reversed reliably with surgery or medication.
Centris Pharmaceuticals Inc pledges to support those affected by the usage of these products, including surgery or a payment waiver for those who find themselves dependent on Enhanced Profile Estrogen-A for their mental health.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report online: [www.fda.gov/medwatch/report.htm](please don’t do this)
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-888-FDA-0178
Comments
2 responses to “EPE”
@Violet
“Where did you get boobs that big?
“Uhh… Upstate New York”
“Well I’m from Utica and I’ve never seen anyone with boobs as big as those”
“It’s an Albany expression”
“I see…”
@violet ooh that’s a good read ~ :latex_heart: